120 results
8-K
EX-1.1
MREO
Mereo Biopharma Group Plc
14 Jun 24
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
4:30pm
, to the extent applicable); (b) the judgment is for a sum payable in respect of taxes, or other charges of a like nature or is in respect of a fine … , such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i
424B5
MREO
Mereo Biopharma Group Plc
14 Jun 24
Prospectus supplement for primary offering
4:15pm
entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated operating losses since formation … , including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
is for a sum payable in respect of taxes, or other charges of a like nature or is in respect of a fine or other penalty or otherwise based on a foreign law … , imposts, fees, assessments or governmental charges of whatever nature (other than taxes on net income) unless the Company is or becomes required
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising), or any … of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
financial statements.
MEREO BIOPHARMA GROUP PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Nature of business
Mereo … and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.
The following table summarizes the Company’s
DEF 14A
8e4j3kte5
24 Apr 24
Definitive proxy
7:30am
10-K
EX-4.2
ivbt18vs3
27 Mar 24
Annual report
5:20pm
10-K
86qe59xv
27 Mar 24
Annual report
5:20pm
10-K
EX-10.30
d94 zhjopm
27 Mar 24
Annual report
5:20pm
6-K
EX-3.1
l7b ckx4p
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.2
g2osk3qm
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
vstmvokj06oaql
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
isw0h3
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
4xxzegs5 ugafd
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-3.1
qtwui3r1 k4
17 May 22
Current report (foreign)
8:26am
6-K
xigc7n33c d54xrvx2u
17 May 22
Current report (foreign)
8:26am